Lymphoma: all 5,624 studies
Page 26 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- A Study of KRN125 in Patients With Multiple Myeloma and Malignant LymphomaCompletedNCT05007652Phase 2
- Brentuximab Vedotin in Combination With CHEP in Patient With PTCLStatus unknownNCT05006664Phase 2
- Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell LymphomaCompletedNCT05006534
- The Performance of Multi-tracer Multimodality PET in LymphomaStatus unknownNCT05004961
- PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell MalignanciesStatus unknownNCT05003141Phase 1
- A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.Status unknownNCT04999878Phase 4
- A Survey Exploring Health and Screening Tests in People Treated for Hodgkin LymphomaCompletedNCT04996862
- CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHLWithdrawnNCT04995536Phase 1
- Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3)Status unknownNCT04990856Not applicable
- Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell LymphomaWithdrawnNCT04990778Phase 2
- A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin LymphomasTerminatedNCT04986865Phase 1
- Lung Screening in People Cured of Hodgkin LymphomaCompletedNCT04986189Not applicable
- Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort StudyTerminatedNCT04982471
- realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCLCompletedNCT04981795
- Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or LymphomaCompletedNCT04977167Phase 1
- SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerActive, not recruitingNCT04977024Phase 2
- A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
- A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or LymphomaCompletedNCT04970992Phase 1
- Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and LeukemiaWithdrawnNCT04961801Phase 1/2
- B-cell Chronic Lymphoid Malignancies MarkersStatus unknownNCT04952974
- Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive LymphomasWithdrawnNCT04952584Phase 1
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownNCT04948788Phase 2
- Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-NimTerminatedNCT04947618
- JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived AsparaginaseApproved for marketingNCT04943952
- Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell MalignancesStatus unknownNCT04934774Phase 1
- Total-body PET / CT in the Evaluation of Treatment and Prognosis of LymphomaStatus unknownNCT04931875
- Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ LymphomaStatus unknownNCT04928105Not applicable
- Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell LymphomaCompletedNCT04918940Not applicable
- GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaStatus unknownNCT04917250Phase 2
- Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaStatus unknownNCT04916860Not applicable
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Active, not recruitingNCT04914741Phase 1/2
- the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After ChemotherapyStatus unknownNCT04914143Not applicable
- Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in LymphomaStatus unknownNCT04910594Phase 3
- Leukemic Phase of ALCLStatus unknownNCT04908059
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLStatus unknownNCT04899453Phase 2
- Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04899427Phase 2
- Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell LymphomaStatus unknownNCT04899414Phase 2
- Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's LymphomaStatus unknownNCT04897477Phase 1/2
- IIT2020-20-SHIRAZIP-WALK: Nature WalksCompletedNCT04896580Not applicable
- Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's LymphomaStatus unknownNCT04893538
- Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDGActive, not recruitingNCT04892667Not applicable
- Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedNCT04890236Early Phase 1
- A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)CompletedNCT04887519
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnNCT04882163Phase 1/2
- An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or LymphomaStatus unknownNCT04873440Phase 1/2
- Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH TrialCompletedNCT04872413Not applicable
- A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBLWithdrawnNCT04860817Early Phase 1
- A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area LymphomaStatus unknownNCT04860674Phase 2
- A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT04860466Phase 1
- Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or RegionCompletedNCT04859920
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04852822
- A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT04849715Phase 3
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Phase 2
- A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04845139Not applicable
- RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid MalignanciesTerminatedNCT04844086Phase 1
- Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical StudyStatus unknownNCT04842318Phase 4
- A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSLCompletedNCT04841434Phase 1/2
- Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphomaCompletedNCT04840875Phase 1
- A Study of Brentuximab Vedotin in Adults With CD30-positive LymphomaCompletedNCT04837222
- Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT04836832Phase 1
- Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
- A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System LymphomaStatus unknownNCT04831658Phase 1/2
- Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesSuspendedNCT04828174Phase 1
- A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced CancerSuspendedNCT04827810Phase 1
- A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell LymphomaStatus unknownNCT04827004Phase 2
- Gene Abnormalities and Prognosis in Diffuse Large B-cell LymphomaStatus unknownNCT04825899
- Telerehabilitation and Lymphoma PatientsCompletedNCT04822389Not applicable
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownNCT04818372Phase 1
- CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell LymphomaCompletedNCT04812691Phase 1
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT04806035Phase 1
- Secondary Prognostic Index in RefrActory LymphomaStatus unknownNCT04804865
- Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersTerminatedNCT04804254Phase 1
- Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With LymphomaStatus unknownNCT04797182Phase 2
- To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)WithdrawnNCT04796922Phase 3
- Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCLStatus unknownNCT04796857Phase 1/2
- Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
- A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT04790903Phase 1
- a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell LymphomaStatus unknownNCT04782193Phase 1/2
- Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
- Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin LymphomaTerminatedNCT04775680Phase 1/2
- Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedNCT04774068Phase 1
- Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade LymphomasStatus unknownNCT04773769Not applicable
- Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic MalignanciesStatus unknownNCT04767308Early Phase 1
- Tumor Heterogeneity in Diffuse Large B-cell Lymphoma in Relation to CNS Involvement and Cell-free DNACompletedNCT04763148
- Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in SwedenCompletedNCT04760184
- Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic MalignanciesCompletedNCT04748185
- Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Phase 1/2
- Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)SuspendedNCT04746131Phase 1
- Mogamulizumab Q4week Dosing in Participants With R/R CTCLActive, not recruitingNCT04745234Phase 2
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- A Phase 1 Study of ADI-001 in B Cell MalignanciesTerminatedNCT04735471Phase 1
- DLBCL Treatment in Children and AdolescentsCompletedNCT04726995
- Dual Target CAR-T Cells in B-cell LymphomaStatus unknownNCT04723914Phase 1/2
- A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)TerminatedNCT04718675Phase 1/2
- Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological CancerTerminatedNCT04716153Not applicable
- Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaActive, not recruitingNCT04712864Phase 1
- A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular LymphomaStatus unknownNCT04707079Phase 2
- Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNo longer availableNCT04705454